(HealthDay)—For persons with a history of previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the neutralizing antibody titer is higher after one dose of mRNA vaccine than after two vaccine doses among previously uninfected persons, according to a research letter published online April 14 in the New England Journal of Medicine.
Gabriele Anichini, from the University of Siena in Italy, and colleagues conducted an observational cohort study involving 100 health care workers, including 38 who had a documented history of SAR-CoV-2 infection and 62 who had not been previously infected. Both groups received the mRNA vaccine BNT162b2. Serum samples were obtained 10 days after administration of the first dose in previously infected participants and 10 days after the second dose in previously uninfected participants.
The researchers observed no significant difference in circulating anti-spike immunoglobulin G antibody titers between the samples from previously infected and uninfected participants (mean level: 20,120 and 22,639 arbitrary units/mL, respectively). Samples from previously infected participants had significantly higher levels of neutralizing antibodies than those from previously uninfected participants (geometric mean titer: 569 versus 118).
“These findings provide evidence that after the administration of a single dose of vaccine, the humoral response against SARS-CoV-2 in persons with a history of SARS-CoV-2 infection is greater than the response in previously uninfected participants who have received a second dose,” the authors write.
COVID-19 survivors might need just one dose of two-part vaccine
Copyright © 2021 HealthDay. All rights reserved.
Response to one COVID-19 vaccine dose strong in previously infected (2021, April 16)
retrieved 17 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022